🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

49 results for “Turn” Clear

  1. ALN-CFB

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  2. ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule active

    1 trial

  3. BCX9930

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule terminated

    3 trials

  4. Coversin

    Akari Therapeutics Plc

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

  5. Coversin

    Akari Therapeutics Plc

    Paroxysmal Nocturnal Haemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

  6. Crovalimab, Crovalimab, Crovalimab Placebo F01-01, Crovalimab

    Hoffmann-La Roche

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  7. Eculizumab

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule terminated

    1 trial

  8. GX-03

    Turn Therapeutics

    Covid19

    phase 2 small molecule completed

    1 trial

  9. GX-03

    Turn Therapeutics

    Eczema Atopic Dermatitis

    phase 2 other active

    1 trial

  10. Pegcetacoplan

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule active

    2 trials

  11. Placebo

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule terminated

    1 trial

  12. REGN3918

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

  13. Repotrectinib (TPX-0005)

    Turn Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  14. Repotrectinib (TPX-0005), Repotrectinib (TPX-0005), Repotrectinib (TPX-0005)

    Turn Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  15. Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection, modified recombinant human C-type natriuretic peptide (rhCNP)

    BioMarin Pharmaceutical Australia Pty Ltd

    Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome

    phase 2 small molecule active

    1 trial

  16. growth hormone

    Ultragenyx UK Limited

    Turner's Syndrome

    phase 2 small molecule completed

    1 trial

  17. A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

    Oncopeptides AB (publ)

    Recurrent glioblastoma

    phase 1 other active

    1 trial

  18. BCX10013

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria

    phase 1 small molecule completed

    1 trial

  19. First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterations in MET

    Turn Therapeutics

    Phase 1: Advanced solid tumors harboring genetic alterations in MET

    phase 1 other active

    1 trial

  20. This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  21. COMBINATIONS

    Disc Medicine

    muscle protein turnover hemodialysis

    approved small molecule active

    1 trial

  22. SCE-B

    Teva Pharma GmbH

    Nocturnal Vasomotor Symptoms

    approved small molecule completed

    1 trial

  23. Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Disc Medicine

    Paroxysmal nocturnal hemoglobinuria (PNH)

    approved small molecule active

    1 trial

  24. Estrogen

    Ultragenyx UK Limited

    Turner's Syndrome

    small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources